Printer Friendly

ALPHA 1 BIOMEDICALS, INC. ANNOUNCES

 BETHESDA, Md., June 29 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) is pleased to announce that the Italian government has granted marketing approval for Thymosin alpha 1 in Italy. This is the first commercial approval of the company's lead product, Thymosin alpha 1.
 Vincent F. Simmon, Ph.D., president and CEO of Alpha 1, stated: "The approval to market Thymosin alpha 1 in Italy is a major milestone which we had anticipated for this year. Actual sales are not anticipated until the fourth quarter or early 1994, because of the need to obtain regulatory approval to export Thymosin for commercial sales. Although the initial indication for which Thymosin was approved represents a small patient population, there will be additional submissions in 1993 and 1994 for additional indications."
 The marketing approval was granted to Sclavo S.p.A. (Siena, Italy), the company's Italian licensee, for the use of Thymosin alpha 1 as an adjuvant for influenza vaccine in patients undergoing renal dialysis. Sclavo also is sponsoring clinical trials in Italy using Thymosin alpha 1 for the treatment of chronic hepatitis B, chronic hepatitis C, cancer and AIDS. Sclavo intends to submit preliminary data from combination therapy trials in lung cancer and melanoma to the Italian Ministry of Health in the next few months. A five-center trial in Italy using Thymosin alpha 1 for the treatment of chronic hepatitis B is expected to be completed during the second half of 1993. If the trial is successful, the marketing approval for chronic hepatitis B indication could occur by mid-1994 in Italy, according to Sclavo. In addition, the Italian Ministry of Health has initiated a 200 patient multi-center trial using Thymosin alpha 1 for the treatment of HIV infection.
 Thymosin alpha 1 is currently the subject of an Alpha 1-sponsored multi-center Phase III trial for the treatment of chronic hepatitis B in the U.S. Alpha 1 is also sponsoring U.S. clinical trials with Thymosin alpha 1 in combination with other drugs for the treatment of chronic active hepatitis C and AIDS.
 -0- 6/29/93
 /CONTACT: Vincent F. Simmon, Ph.D., president and CEO of Alpha 1 Biomedicals, 301-564-4400, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedical/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU:

PS-LG -- NY017 -- 6595 06/29/93 09:44 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:389
Previous Article:REGISTRATION STATEMENT COVERING SECONDARY OFFERING OF 4 MILLION MAGMA POWER COMPANY SHARES NOW EFFECTIVE
Next Article:ACE HARDWARE SELECTS GOLDEN EAGLE
Topics:


Related Articles
ALPHA 1 BIOMEDICALS APPOINTS HAUTALA TO VICE PRESIDENT, CORPORATE DEVELOPMENT
ALPHA 1 BIOMEDICALS ANNOUNCES 1991 FINANCIAL RESULTS
ALPHA 1 BIOMEDICALS ANNOUNCES REDEMPTION OF CLASS B WARRANTS
ALPHA 1 BIOMEDICALS, INC. FIRST QUARTER CALENDAR YEAR 1993 RESULTS
ALPHA 1 BIOMEDICALS SECOND QUARTER, CALENDAR YEAR 1993 RESULTS
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES
CEL-SCI AND ALPHA 1 REACQUIRE FAR EASTERN RIGHTS TO HIV CANDIDATE VACCINE
Alpha 1 Biomedicals, Inc. Concludes Private Financing and Funds New Study
Alpha 1 Biomedicals, Inc. Calendar Year 1996 Results
Alpha 1 Biomedicals, Inc. Third Quarter Calendar Year 1997 Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters